ES2342778T3 - Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus. - Google Patents

Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus. Download PDF

Info

Publication number
ES2342778T3
ES2342778T3 ES04778847T ES04778847T ES2342778T3 ES 2342778 T3 ES2342778 T3 ES 2342778T3 ES 04778847 T ES04778847 T ES 04778847T ES 04778847 T ES04778847 T ES 04778847T ES 2342778 T3 ES2342778 T3 ES 2342778T3
Authority
ES
Spain
Prior art keywords
baselineskip
seq
polypeptide
orf0657n
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04778847T
Other languages
English (en)
Spanish (es)
Inventor
Annaliesa S. Anderson
Kathrin Ute Jansen
Rosemarie Kelly
Loren D. Schultz
Donna L. Montgomery
William L. Mcclements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2342778(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2342778T3 publication Critical patent/ES2342778T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES04778847T 2003-07-24 2004-07-22 Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus. Expired - Lifetime ES2342778T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US489840P 2003-07-24
US52011503P 2003-11-14 2003-11-14
US520115P 2003-11-14

Publications (1)

Publication Number Publication Date
ES2342778T3 true ES2342778T3 (es) 2010-07-14

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04778847T Expired - Lifetime ES2342778T3 (es) 2003-07-24 2004-07-22 Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus.

Country Status (23)

Country Link
US (2) US20060177462A1 (https=)
EP (1) EP1651166B8 (https=)
JP (1) JP2007502101A (https=)
KR (1) KR20060065643A (https=)
AT (1) ATE457737T1 (https=)
AU (1) AU2004258979B2 (https=)
BR (1) BRPI0412799A (https=)
CA (1) CA2532370A1 (https=)
CY (1) CY1110028T1 (https=)
DE (1) DE602004025579D1 (https=)
DK (1) DK1651166T3 (https=)
ES (1) ES2342778T3 (https=)
HR (1) HRP20100240T1 (https=)
IL (1) IL173253A0 (https=)
IS (1) IS8213A (https=)
MX (1) MXPA06000854A (https=)
NO (1) NO20060898L (https=)
NZ (2) NZ570750A (https=)
PL (1) PL1651166T3 (https=)
PT (1) PT1651166E (https=)
RU (1) RU2337108C2 (https=)
SI (1) SI1651166T1 (https=)
WO (1) WO2005009379A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2005214061B2 (en) * 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
EP1812066A4 (en) * 2004-10-25 2010-06-30 Univ Western Ontario STAINLOCOCCUS AUREUS-BASED ANTI-INFECTION AGENTS ON ISD PROTEIN
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CN101375161A (zh) * 2006-01-27 2009-02-25 默克公司 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白
EP2117574A4 (en) 2007-01-24 2010-06-16 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS EPIDERMIDIS
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
AU2009319947A1 (en) 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20130004539A1 (en) * 2010-03-12 2013-01-03 Jeffrey Weiser Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
EP2593133A4 (en) 2010-07-13 2014-11-26 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
SG11201400210RA (en) 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
EP2773370A4 (en) 2011-10-31 2016-09-28 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2451
MX354862B (es) * 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
JP4424984B2 (ja) * 2001-06-15 2010-03-03 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体
ATE421977T1 (de) * 2001-11-12 2009-02-15 Novo Nordisk As Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
JP2005532415A (ja) * 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
ATE457737T1 (de) 2010-03-15
JP2007502101A (ja) 2007-02-08
RU2006105498A (ru) 2006-09-10
WO2005009379A2 (en) 2005-02-03
EP1651166A4 (en) 2008-03-05
KR20060065643A (ko) 2006-06-14
AU2004258979B2 (en) 2007-12-06
AU2004258979A1 (en) 2005-02-03
US20100247561A1 (en) 2010-09-30
EP1651166A2 (en) 2006-05-03
EP1651166B8 (en) 2010-05-19
WO2005009379A3 (en) 2006-11-30
PL1651166T3 (pl) 2010-08-31
PT1651166E (pt) 2010-04-23
CY1110028T1 (el) 2015-01-14
BRPI0412799A (pt) 2006-09-26
EP1651166B1 (en) 2010-02-17
CA2532370A1 (en) 2005-02-03
HRP20100240T1 (hr) 2010-09-30
NZ570750A (en) 2009-12-24
RU2337108C2 (ru) 2008-10-27
MXPA06000854A (es) 2006-03-30
SI1651166T1 (sl) 2010-06-30
IS8213A (is) 2005-12-30
DE602004025579D1 (de) 2010-04-01
NO20060898L (no) 2006-04-24
NZ544542A (en) 2009-01-31
US20060177462A1 (en) 2006-08-10
IL173253A0 (en) 2006-06-11
DK1651166T3 (da) 2010-05-31

Similar Documents

Publication Publication Date Title
ES2342778T3 (es) Polipeptidos para la induccion de una respuesta inmunitaria de proteccion contra staphylococcus aureus.
AU2005214061B2 (en) Polypeptides for inducing a protective immune response against Staphylococcus aureus
RU2186109C2 (ru) Полинуклеотидная противотуберкулезная вакцина
ZA200600247B (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
US20100203588A1 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
US20080095792A1 (en) Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
US20070243205A1 (en) Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
US20070264278A1 (en) Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
US20070172498A1 (en) Polypeptides for inducing a protective immune response against staphyloococcus aureus
EP2638058B1 (en) Enolase peptide conjugate vaccines against staphylococcus aureus
KR20200046059A (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
CA2681035A1 (en) Polypeptides for inducing a protective immune response against staphylococcus epidermidis
WO2006121664A2 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1784212A2 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus